Trial Profile
Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Jul 2020
Price :
$35
*
At a glance
- Drugs Fulranumab (Primary)
- Indications Musculoskeletal pain
- Focus Registrational; Therapeutic Use
- Acronyms PAI3003
- Sponsors Janssen Research & Development
- 23 May 2016 Planned End Date changed from 1 Sep 2018 to 1 Sep 2016.
- 23 May 2016 Planned End Date changed from 1 Jan 2018 to 1 Sep 2018.
- 23 May 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Sep 2016.